This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) | MicrobiomeTrials
← Back to trials NCT07357727
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) Recruiting PHASE3 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-05-27Est. Completion: 2028-05-17
Enrollment target: 460 participantsLocations Rocky Mountain Cancer Centers, Denver, Colorado, United States Yale University School Of Medicine, New Haven, Connecticut, United States Florida Cancer Specialist South Reg, Fort Myers, Florida, United States The Anderson Family Cancer Institute, Jupiter, Florida, United States Miami NS Ins Baptist Health S FL, Miami, Florida, United States Florida Cancer Specialists-North, St. Petersburg, Florida, United States Florida Cancer Specialists East, Stuart, Florida, United States Winship Cancer Institute of Emory University, Atlanta, Georgia, United States University of Chicago Hospital, Chicago, Illinois, United States Franciscan Health Indianapolis, Indianapolis, Indiana, United States American Oncology Partners PA Center for Cancer and Blood Disorders, Bethesda, Maryland, United States Summit Medical Group Oncology, Berkeley Heights, New Jersey, United States New York Oncology Hematology P C, Albany, New York, United States Columbia University Medical Center New York Presbyterian, New York, New York, United States The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States Other microbiome trials you might be interested in Primary Myelofibrosis Post-essential Thrombocythemia Myelofibrosis Post-polycythemia Vera Myelofibrosis
This is a phase II, open label, prospective, single-arm study evaluating the efficacy and safety of selinexor in patient…
Salt Lake City, United States Completed Aug 16, 2023
Myelofibrosis Myelofibrosis Due to and Following Polycythemia Vera Myelofibrosis Transformation in Essential Thrombocythemia Myelofibrosis With High Molecular Risk Mutations Myelofibrosis With Myeloid Metaplasia
Texas Oncology - Central South, Austin, Texas, United States
Texas Oncology PA Dallas Presbyterian Hospital, Dallas, Texas, United States
MD Anderson Cancer Center, Houston, Texas, United States
SCRI Texas Oncology Northeast Texas, Tyler, Texas, United States
Fred Hutch Cancer Research, Seattle, Washington, United States
Hospital de Clinicas Jose de San Martin, Buenos Aires, Buenos Aires F.D., Argentina
Hospital Italiano de Buenos Aires, CABA, Argentina
FUNDALEU, Capital Federal, Argentina
Hospital Privado de Cordoba, Córdoba, Argentina
Novartis Investigative Site, Adelaide, South Australia, Australia
Novartis Investigative Site, Clayton, Victoria, Australia
Novartis Investigative Site, Graz, Austria
Novartis Investigative Site, Salzburg, Austria
Novartis Investigative Site, Sankt Pölten, Austria
Novartis Investigative Site, Vienna, Austria
Novartis Investigative Site, Woluwe-Saint-Lambert, Brussels Capital, Belgium
Novartis Investigative Site, Goiânia, Goiás, Brazil
Novartis Investigative Site, Curitiba, Paraná, Brazil
Grupo ELORA, Florianópolis, Santa Catarina, Brazil
Novartis Investigative Site, Barretos, São Paulo, Brazil
Jewish General Hospital, Montreal, Quebec, Canada
Novartis Investigative Site, Hefei, Anhui, China
Novartis Investigative Site, Guangzhou, Guangdong, China
Novartis Investigative Site, Guangzhou, Guangdong, China
Novartis Investigative Site, Wuhan, Hubei, China
Novartis Investigative Site, Wuhan, Hubei, China
Novartis Investigative Site, Nanjing, Jiangsu, China
Novartis Investigative Site, Nantong, Jiangsu, China
Novartis Investigative Site, Nanchang, Jiangxi, China
Novartis Investigative Site, Changchun, Jilin, China
Novartis Investigative Site, Jinan, Shandong, China
Novartis Investigative Site, Yantai, Shandong, China
Novartis Investigative Site, Kunming, Yunnan, China
Novartis Investigative Site, Hangzhou, Zhejiang, China
Novartis Investigative Site, Wenzhou, Zhejiang, China
Novartis Investigative Site, Beijing, China
Novartis Investigative Site, Chongqing, China
Novartis Investigative Site, Fuzhou, China
Novartis Investigative Site, Shanghai, China
Novartis Investigative Site, Shenyang, China
Novartis Investigative Site, Tianjin, China
Novartis Investigative Site, Ostrava, Poruba, Czechia
Novartis Investigative Site, Brno, Czechia
Novartis Investigative Site, Hradec Králové, Czechia
Novartis Investigative Site, Olomouc, Czechia
Novartis Investigative Site, Brest, France
Novartis Investigative Site, Le Kremlin-Bicêtre, France
Novartis Investigative Site, Lens, France
Novartis Investigative Site, Nîmes, France
Novartis Investigative Site, Paris, France
Novartis Investigative Site, Pessac, France
Novartis Investigative Site, Poitiers, France
Novartis Investigative Site, Rennes, France
Novartis Investigative Site, Toulouse, France
Novartis Investigative Site, Mannheim, Baden-Wurttemberg, Germany
Novartis Investigative Site, Aachen, Germany
Novartis Investigative Site, Cottbus, Germany
Novartis Investigative Site, Erlangen, Germany
Novartis Investigative Site, Hamburg, Germany
Novartis Investigative Site, Aurangabad, Maharashtra, India
Novartis Investigative Site, Pune, Maharashtra, India
Novartis Investigative Site, Rishikesh, Uttarakhand, India
Novartis Investigative Site, Kolkata, West Bengal, India
Novartis Investigative Site, Delhi, India
Novartis Investigative Site, Meldola, FC, Italy
Novartis Investigative Site, Florence, FI, Italy
Novartis Investigative Site, Monza, MB, Italy
Novartis Investigative Site, Palermo, PA, Italy
Novartis Investigative Site, Padova, PD, Italy
Novartis Investigative Site, Roma, RM, Italy
Novartis Investigative Site, Verona, VR, Italy
Novartis Investigative Site, Novara, Italy
Novartis Investigative Site, Kamogawa, Chiba, Japan
Novartis Investigative Site, Sapporo, Hokkaido, Japan
Novartis Investigative Site, Kobe, Hyōgo, Japan
Novartis Investigative Site, Shiwa-Gun, Iwate, Japan
Novartis Investigative Site, Tsu, Mie-ken, Japan
Novartis Investigative Site, Kurashiki, Okayama-ken, Japan
Novartis Investigative Site, Bunkyo Ku, Tokyo, Japan
Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan
Novartis Investigative Site, Chūō, Yamanashi, Japan
Novartis Investigative Site, Fukuoka, Japan
Novartis Investigative Site, Kumamoto, Japan
Novartis Investigative Site, Miyazaki, Japan
Novartis Investigative Site, George Town, Pulau Pinang, Malaysia
Novartis Investigative Site, Kota Kinabalu, Sabah, Malaysia
Novartis Investigative Site, Kuching, Sarawak, Malaysia
Novartis Investigative Site, Johor Bahru, Malaysia
Novartis Investigative Site, Kuala Selangor, Malaysia
Novartis Investigative Site, Amsterdam, North Holland, Netherlands
Novartis Investigative Site, Utrecht, Netherlands
Novartis Investigative Site, Gdansk, Poland
Novartis Investigative Site, Katowice, Poland
Novartis Investigative Site, Lublin, Poland
Novartis Investigative Site, Skorzewo, Poland
Novartis Investigative Site, Torun, Poland
Novartis Investigative Site, Warsaw, Poland
Novartis Investigative Site, Wałbrzych, Poland
Novartis Investigative Site, Suwon, Gyeonggi-do, South Korea
Novartis Investigative Site, Jeonju, Jeollabuk-do, South Korea
Novartis Investigative Site, Seoul, Yangcheon Gu, South Korea
Novartis Investigative Site, Busan, South Korea
Novartis Investigative Site, Seoul, South Korea
Novartis Investigative Site, Seoul, South Korea
Novartis Investigative Site, Seoul, South Korea
Novartis Investigative Site, Seoul, South Korea
Novartis Investigative Site, Donostia / San Sebastian, Gipuzkoa, Spain
Novartis Investigative Site, El Palmar, Murcia, Spain
Novartis Investigative Site, Pamplona, Navarre, Spain
Novartis Investigative Site, Alicante, Spain
Novartis Investigative Site, Barcelona, Spain
Novartis Investigative Site, Las Palmas GC, Spain
Novartis Investigative Site, Madrid, Spain
Novartis Investigative Site, Málaga, Spain
Novartis Investigative Site, Salamanca, Spain
Novartis Investigative Site, Basel, Switzerland
Novartis Investigative Site, Bern, Switzerland
Novartis Investigative Site, Geneva, Switzerland
Novartis Investigative Site, Genolier, Switzerland
Novartis Investigative Site, Changhua, Taiwan
Novartis Investigative Site, Kaohsiung City, Taiwan
Novartis Investigative Site, Tainan, Taiwan
Novartis Investigative Site, Taipei, Taiwan
Novartis Investigative Site, Sakarya, Adapazari, Turkey (Türkiye)
Novartis Investigative Site, Istanbul, Fatih, Turkey (Türkiye)
Novartis Investigative Site, Ankara, Kecioren, Turkey (Türkiye)
Novartis Investigative Site, Bursa, Nilufer, Turkey (Türkiye)
Novartis Investigative Site, Istanbul, Pendik, Turkey (Türkiye)
Novartis Investigative Site, Ankara, Sihhiye Altindag, Turkey (Türkiye)
Novartis Investigative Site, Ankara, Turkey (Türkiye)
Novartis Investigative Site, Izmir, Turkey (Türkiye)
Novartis Investigative Site, Kocaeli, Turkey (Türkiye)
Novartis Investigative Site, Samsun, Turkey (Türkiye) Myelofibrosis, Post ET
Myelofibrosis, Post PV
Myelofibrosis, Primary
Myelofibrosis; Anemia
Myelofibrosis，MF
Myelofibrosis (PMF)
Myeloid Metaplasia
The goal of this clinical trial is to learn which of three different doses of Flonoltinib Maleate taken by mouth daily w…
Multiple Locations Est. completion Nov 2028